<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02456454</url>
  </required_header>
  <id_info>
    <org_study_id>CHMC#03-12-26</org_study_id>
    <nct_id>NCT02456454</nct_id>
  </id_info>
  <brief_title>Controlled Trial of Valproate Versus Risperidone in Young Children With Bipolar Disorder</brief_title>
  <official_title>Placebo Controlled Trial of Valproate Versus Risperidone in Young Children With Bipolar Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nationwide Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanley Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nationwide Children's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Controlled trial of the efficacy and safety of valproate, versus risperidone in children,
      ages 3-7 yr. with Bipolar I or II Disorder, mixed, manic or hypomanic episode.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study was to study the efficacy and safety of valproate, versus
      risperidone in children, ages 3-7 yr. with Bipolar I or II Disorder, mixed, manic or
      hypomanic episode.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Young Mania Rating Scale</measure>
    <time_frame>6 weeks</time_frame>
    <description>Young Mania Rating Scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Improvement Scale</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Risp</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Risperidone, PO 0.25-2 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valproic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Valproic Acid PO to achieve plasma levels of 85-100</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCB</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Liquid placebo PO matched for color and taste.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <description>Liquid risperidone</description>
    <arm_group_label>Risp</arm_group_label>
    <other_name>Risperdal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valproic Acid</intervention_name>
    <description>Liquid valproic acid</description>
    <arm_group_label>Valproic</arm_group_label>
    <other_name>Valproate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Valproic Acid</intervention_name>
    <description>PCB</description>
    <arm_group_label>PCB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Subjects were male or female outpatient subjects,

          -  3.0 - 7 years 11 months of age

          -  Bipolar I or II Disorder, mixed, manic or hypomanic episode, psychotic or
             non-psychotic, according to DSM IV criteria (American Psychiatric Association 1994)

          -  with a score &gt; 20 on the Young Mania Rating Scale (YMRS.

        Exclusion Criteria

          -  clinically significant or unstable hepatic, renal, gastroenterological, respiratory,
             cardiovascular, endocrinologic, immunologic, hematologic or other systemic medical
             conditions;

          -  neurologic disorders including epilepsy, stroke, or severe head trauma those
             clinically significant laboratory abnormalities, on any of the following tests:

               -  CBC with differential,

               -  electrolytes,

               -  BUN,

               -  creatinine,

               -  hepatic transaminases,

               -  urinalysis,

               -  thyroid indices (T3, Total T4, Free T4, TSH) and

               -  EKG

          -  mania due to a general medical condition or substance-induced mania

          -  mental retardation (IQ &lt;70),

          -  evidence of Fetal Alcohol Syndrome or an Alcohol-Related Neurodevelopmental Disorder,

          -  Schizophrenia or other psychotic disorders (including schizophreniform disorder,
             schizoaffective disorder, delusional disorder, brief psychotic disorder, shared
             psychotic disorder, psychotic disorder due to a general medical condition,
             substance-induced psychotic disorder, psychotic disorder not otherwise specified) as
             defined in the DSM-IV.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>7 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert A Kowatch, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nationwide Children's Hospital</affiliation>
  </overall_official>
  <results_reference>
    <citation>Kowatch RA, Scheffer RE, Monroe E, Delgado S, Altaye M, Lagory D. Placebo-controlled trial of valproic Acid versus risperidone in children 3-7 years of age with bipolar I disorder. J Child Adolesc Psychopharmacol. 2015 May;25(4):306-13. doi: 10.1089/cap.2014.0166.</citation>
    <PMID>25978742</PMID>
  </results_reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2015</study_first_submitted>
  <study_first_submitted_qc>May 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2015</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nationwide Children's Hospital</investigator_affiliation>
    <investigator_full_name>Robert Kowatch</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

